Description
Last week, Autolus announced that they had received FDA approval for their autologous CAR-T cell therapy obe-cel (AUCATZYL) for use in adult r/r B-ALL. This is amazing news for the patients and the company – congrats to both!
In this video, I explain the data that led to the approval and the significance of Autolous’ CAR-T technology.
The “fast off rate” of their CAR receptors makes them an attractive therapeutic candidate especially for patients with autoimmunity.
Discover how Innate Pharma’s NK Cell Engager (NKCE-IL2v) enhances NK cell activity, outcompeting T cell engagers in vitro, offering new...
Video description T cell exhaustion can severely hinder anti-cancer immune responses and several therapeutic modalities - including the most successful...
Video Description Over the past few months, several major biotech and pharmaceutical companies have made headlines with their advancements in...
Video Description Welcome to Emerging Biotech: Today's Insights Into Tomorrow's Cancer Therapies. I'm Jeff, Founder here at Oncoleader. In this...
